4.4 Article

Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells

Journal

ANTI-CANCER DRUGS
Volume 21, Issue 6, Pages 619-624

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0b013e328339848b

Keywords

apicidin; cervical cancer; prolyl hydroxylase

Funding

  1. Polish Ministry of Science and Higher Education [N N407 090236]

Ask authors/readers for more resources

It was recently reported that the reduced expression of hypoxia-inducible factor prolyl 4-hydroxylase PHD2 in human cancers correlates with increased angiogenesis. We used HeLa, CaSki, C33A, and SiHa cervical cancer cells to show the effect of apicidin on cellular levels of PHD2 enzyme. Using reverse transcription, real-time quantitative PCR, and western blot analysis, we established that apicidin upregulates PHD2 transcript and protein levels in HeLa, CaSki, and C33A, but not in SiHa cervical cancer cells. Bisulfite sequencing showed that the increase in PHD2 expression was accompanied by demethylation of CpG islands located in the first exon of the PHD2 gene. As decreased PHD2 expression supports tumor progression, our findings may validate the usefulness of apicidin as an anticancer drug. Anti-Cancer Drugs 21:619-624 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available